The Role of MLC901 in Reducing VEGF As a Vascular Permeability Marker in Rats with Spinal Cord Injury

Overview

Journal Ann Med Surg (Lond)

Publisher Wolters Kluwer

Specialty Medical Education

Date 2022 Apr 7

PMID 35386787

Authors

Wahyudi

Andi Asadul Islam

Mochammad Hatta

Willy Adhimarta

Muhammad Faris

Nasrullah Mustamir

Agussalim Bukhari

Prihantono

Cahyono Kaelan

Joko Hendarto

Naufal Hilmy Imran

Rohadi Muhammad Rosyidi

Affiliations

Soon will be listed here.

Abstract

Background: Damaged neural tissue caused by SCI could induce vascular endothelial growth factor (VEGF) that can worsen the condition in the late phase by increasing vascular permeability, thus inducing tissue oedema, which can worsen the infarction. MLC 901 has been widely used in Asia for stroke patients because its mechanism is known to down-regulate VEGF levels in ischemic tissue.

Methods: Ten Sprague-Dawley rats were used in this experiment. To create a severe spinal cord injury in animal models. The animals were then randomly divided into two groups. MLC 901 was given to the first group, which was the intervention group, and placebo to the second group, which was the control group.

Results: This study showed a decrease in the mean VEGF mRNA expression in the group given MLC 901 compared to the control group, which had a very high mean VEGF mRNA expression starting after 1 h of administration of MLC 901 until day 14 after spinal cord injury. In addition, there was a decrease in VEGF levels in the MLC 901 group compared to the control group from 3 h after spinal cord injury (1 h after MLC 901 administration) to 14 days after spinal cord injury.

Conclusion: It can be concluded that administration of MLC 901 can reduce vascular permeability, one of the mechanisms that is thought to occur is to reduce VEGF levels. MLC 901 also maintains the neuroprotective effect provided by VEGF by maintaining this level above the basal level until day 14.

Citing Articles

NeuroAiD-II (MLC901) Promoted Neurogenesis by Activating the PI3K/AKT/GSK-3β Signaling Pathway in Rat Spinal Cord Injury Models.

Anjum A, Yazid M, Daud M, Idris J, Ng A, Naicker A Biomedicines. 2024; 12(8).

PMID: 39200383 PMC: 11352105. DOI: 10.3390/biomedicines12081920.

Effects of Moleac 901 after severe spinal cord injury on chronic phase in Wistar rats.

Wardhana D, Maliawan S, Mahadewa T, Islam A, Jawi I, Wiradewi Lestari A Heliyon. 2024; 10(7):e28522.

PMID: 38601579 PMC: 11004522. DOI: 10.1016/j.heliyon.2024.e28522.

Facilitation of neurological recovery in a complete spinal cord injury with NeuroAiD: case report.

Zainudin M, Abu Hassan S, Khin N Spinal Cord Ser Cases. 2024; 10(1):16.

PMID: 38570486 PMC: 10991547. DOI: 10.1038/s41394-024-00632-7.

Serum BMP-2 and osteocalcin levels, and CT Hounsfield unit post hyperbaric oxygen therapy in patients with cleft lip and palate post alveolar bone graft: A case study.

Oley M, Oley M, Langi F, Flapper W, Islam A, Hatta M Heliyon. 2023; 9(9):e19955.

PMID: 37809437 PMC: 10559552. DOI: 10.1016/j.heliyon.2023.e19955.

Ginsenoside Rb1 improves energy metabolism after spinal cord injury.

Wen S, Zou Z, Cheng S, Guo H, Hu H, Zeng F Neural Regen Res. 2022; 18(6):1332-1338.

PMID: 36453420 PMC: 9838172. DOI: 10.4103/1673-5374.357915.

References

Peng P, Yu H, Li Y, Huang J, Yao S, Xing C . The emerging role of circular RNAs in spinal cord injury. J Orthop Translat. 2021; 30:1-5. PMC: 8326601. DOI: 10.1016/j.jot.2021.06.001. View

Rosyidi R, Priyanto B, Islam A, Hatta M, Bukhari A, Prihastomo K . Role of MLC901 in increasing neurogenesis in rats with traumatic brain injury. Ann Med Surg (Lond). 2020; 60:36-40. PMC: 7578557. DOI: 10.1016/j.amsu.2020.10.013. View

Melincovici C, Bosca A, Susman S, Marginean M, Mihu C, Istrate M . Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018; 59(2):455-467. View

Ahuja C, Mothe A, Khazaei M, Badhiwala J, Gilbert E, van der Kooy D . The leading edge: Emerging neuroprotective and neuroregenerative cell-based therapies for spinal cord injury. Stem Cells Transl Med. 2020; 9(12):1509-1530. PMC: 7695641. DOI: 10.1002/sctm.19-0135. View

Ogata T, Dohgu S, Takano K, Inoue T, Arima H, Takata F . Increased Plasma VEGF Levels in Patients with Cerebral Large Artery Disease Are Associated with Cerebral Microbleeds. Cerebrovasc Dis Extra. 2019; 9(1):25-30. PMC: 6528098. DOI: 10.1159/000497215. View

Carmeliet P, Jain R . Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011; 473(7347):298-307. PMC: 4049445. DOI: 10.1038/nature10144. View

Hori Y, Ito K, Hamamichi S, Ozawa Y, Matsui J, Umeda I . Functional Characterization of VEGF- and FGF-induced Tumor Blood Vessel Models in Human Cancer Xenografts. Anticancer Res. 2017; 37(12):6629-6638. DOI: 10.21873/anticanres.12120. View

Ranuh I, Sari G, Utomo B, Suroto N, Fauzi A . Systematic Review and Meta-Analysis of the Efficacy of MLC901 (NeuroAiD II) for Acute Ischemic Brain Injury in Animal Models. J Evid Based Integr Med. 2021; 26:2515690X211039219. PMC: 8369951. DOI: 10.1177/2515690X211039219. View

Quintard H, Lorivel T, Gandin C, Lazdunski M, Heurteaux C . MLC901, a Traditional Chinese Medicine induces neuroprotective and neuroregenerative benefits after traumatic brain injury in rats. Neuroscience. 2014; 277:72-86. DOI: 10.1016/j.neuroscience.2014.06.047. View

10.

Guo H, Zhou H, Lu J, Qu Y, Yu D, Tong Y . Vascular endothelial growth factor: an attractive target in the treatment of hypoxic/ischemic brain injury. Neural Regen Res. 2016; 11(1):174-9. PMC: 4774214. DOI: 10.4103/1673-5374.175067. View

11.

Rowland J, Hawryluk G, Kwon B, Fehlings M . Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon. Neurosurg Focus. 2008; 25(5):E2. DOI: 10.3171/FOC.2008.25.11.E2. View

12.

Hachem L, Fehlings M . Pathophysiology of Spinal Cord Injury. Neurosurg Clin N Am. 2021; 32(3):305-313. DOI: 10.1016/j.nec.2021.03.002. View

13.

Bartanusz V, Jezova D, Alajajian B, Digicaylioglu M . The blood-spinal cord barrier: morphology and clinical implications. Ann Neurol. 2011; 70(2):194-206. DOI: 10.1002/ana.22421. View

14.

Lange C, Storkebaum E, Ruiz de Almodovar C, Dewerchin M, Carmeliet P . Vascular endothelial growth factor: a neurovascular target in neurological diseases. Nat Rev Neurol. 2016; 12(8):439-54. DOI: 10.1038/nrneurol.2016.88. View

15.

Heurteaux C, Gandin C, Borsotto M, Widmann C, Brau F, Lhuillier M . Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. Neuropharmacology. 2010; 58(7):987-1001. DOI: 10.1016/j.neuropharm.2010.01.001. View

16.

Ning G, Wu Q, Li Y, Feng S . Epidemiology of traumatic spinal cord injury in Asia: a systematic review. J Spinal Cord Med. 2012; 35(4):229-39. PMC: 3425879. DOI: 10.1179/2045772312Y.0000000021. View

17.

Bae H, Choi W, Hwang A, Lee S, Seong G, Kim C . Effects of Hypoxic Preconditioning and Vascular Endothelial Growth Factor on the Survival of Isolated Primary Retinal Ganglion Cells. Biomolecules. 2021; 11(3). PMC: 8002095. DOI: 10.3390/biom11030391. View

18.

Gandin C, Widmann C, Lazdunski M, Heurteaux C . MLC901 Favors Angiogenesis and Associated Recovery after Ischemic Stroke in Mice. Cerebrovasc Dis. 2016; 42(1-2):139-54. DOI: 10.1159/000444810. View

19.

Benton R, Whittemore S . VEGF165 therapy exacerbates secondary damage following spinal cord injury. Neurochem Res. 2003; 28(11):1693-703. DOI: 10.1023/a:1026013106016. View

20.

Silva N, Sousa N, Reis R, Salgado A . From basics to clinical: a comprehensive review on spinal cord injury. Prog Neurobiol. 2013; 114:25-57. DOI: 10.1016/j.pneurobio.2013.11.002. View